Dr. Reddy's in the news

Carry on, Dr Reddy

his is true for the pharma industry too. At medicine maker Dr. Reddy's - the father, son and son-in-law sit at the governing board table. Their most formidable challenge being Alliances with Western companies

"First Person" with Dr.K.Anji Reddy, Chairman"

First Person with Dr.K.Anji Reddy, Chairman

The Best Companies to work for in India

The good times have started to roll for the pharma major, thanks to some big generic orders, acquisitions and research breakthroughs, but sustainability is what counts.

Most awaited Drugs

Indian companies get ready to serve better and cheaper medicines for asthma to cardiocare and cancer.

Exclusive Interviews - Mr.G.V.Prasad, CEO &Vice-Chairman

The Race to create India's first new drug

Dr. Reddy's diabetes drug is entering the final phase of clinical trials. Three other Indian companies have molecules in advanced phases of testing. They aim to hit the market as early as 2009.

Winners Chronicle Pharma Excellence Awards 2006

Back In The Reckoning

Some smart derisking strategies, a pick up in international markets and better prospects in the US have boosted Dr Reddy’s earning and stock, making it the hot pharma stock that it once was.

The $50 – billion Opportunity

Ranbaxy and Dr. Reddy’s may have found the formula for cracking the US generics market.

Compound Cure

The world's first polypill, a multiple product pill for heart ailments, has been developed by Dr.Reddy's.

Prescription for Success

With the Rs 2,500 crore takeover of a top German pharma firm, Dr Reddy’s Laboratories not only ensures a strategic global presence, but also enters the top-three league on home ground

Great minds think alike

Observers will note clear parellels between Malvinder Singh and Satish Reddy's young business lives - both US-educated, the men have quickly risen to the top of two Indian pharma giants.

Europe Ahoy!

Dr. Reddy’s Laboratories acquires betapharm, Germany’s fourth-largest generic company, for $570 million, in one of the biggest overseas acquisitions by an Indian company.

Generics Make a Name for Themselves

In an otherwise lackluster pharma market, stocks like Dr. Reddy's Labs are surging. With a slather of patents set to expire, their prospects look good.

Family companies form the back bone of the Indian economy

Dr.Reddy's gambit

Frequent drug industry nemesis seeks to boost its custom manufacturing business.